ClinicalTrials.gg
CompletedNCT02815839Updated Feb 28, 2017

Single Dose Study of SHR4640 in Healthy Subjects

A Phase 1 interventional study of SHR4640 and Placebo in Gout; Hyperuricemia, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-02-28.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Nov 2015, registered Apr 2016).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Gout by Jiangsu HengRui Medicine Co., Ltd. — none open to participants now, none under way, none of them phase 3. Gout · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
6th of 11
50 · median 50
Started
2015
the only one that year
Phase 1
7 of 11
none open now
Registered
1st of 11
by date

Among the 11 studies in Gout by Jiangsu HengRui Medicine Co., Ltd., this one is the 6th largest by enrollment, is the only one that started in 2015, is one of 7 in phase 1, and was the 1st registered.

Gout

347 studies on the registry are indexed under Gout; 50 are open to participants now.

Browse Gout studies →

Open to participants now

None of the 11 studies in Gout by Jiangsu HengRui Medicine Co., Ltd. is open now. The open studies under Gout, anywhere →

Where they have run

Who these studies take

Of the 31 Gout studies recruiting now, 14 (45%) set no upper age limit and 10 (32%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Gout by Jiangsu HengRui Medicine Co., Ltd. as a file.
02

Study summary

The objective of the study is to assess the safety, tolerance, food effect, pharmacokinetic and pharmacodynamic properties of single dose adminstration of SHR4640 in healthy volunteers.

03

Conditions studied

  • Gout; Hyperuricemia

Browse trials for

Keywords

  • urate transporter 1
  • SHR4640
  • single ascending dose
  • pharmacokinetics
  • pharmacodynamics
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight≥50, :19-24kg/m2;
  • Screening serum urate level ≤ 4.5 mg/dL for male and ≤ 3.5 mg/dL for female;
  • Medically stable based on physical examination, medical history, laboratory results, vital sign measurements, and 12-lead (ECG) at screening;

Exclusion criteria

Exclusion Criteria:

  • History of hyperuricemia or gout.
  • Pregnancy or breastfeeding;
  • History or suspicion of kidney stones;
  • serum creatinine>1.5mg/dl for male, >1.2mg/dl for female;
  • and/or aspartate aminotransferase>2 , or total >2.5 upper limit of normal.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Cohort 1

    2.5-mg SHR4640 or placebo

    Drug: SHR4640 · Drug: Placebo

  • Experimental
    Cohort 2

    5-mg SHR4640 or placebo

    Drug: SHR4640 · Drug: Placebo

  • Experimental
    Cohort 3

    7.5-mg SHR4640 or placebo

    Drug: SHR4640 · Drug: Placebo

  • Experimental
    Cohort 4

    10-mg SHR4640 or placebo

    Drug: SHR4640 · Drug: Placebo

  • Experimental
    Cohort 5

    20-mg SHR4640 or placebo

    Drug: SHR4640 · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse events

    Time frame: Clinical significant changes from baseline up to to Day 15; from baseline up to Day 19 for 7.5mg dose group

Secondary outcomes

  1. Peak Plasma Concentration (Cmax)

    Time frame: up to day 4; up to day 11 for 7.5mg dose group

  2. Area under the plasma concentration versus time curve (AUC)

    Time frame: up to day 4; up to day 11 for 7.5mg dose group

  3. Half-time (T1/2)

    Time frame: up to day 4; up to day 11 for 7.5mg dose group

  4. Time to the peak plasma concentration (Tmax)

    Time frame: up to day 4; up to day 11 for 7.5mg dose group

  5. Cmax of SHR4640 dosed after high-fat meal in 7.5mg dose group

    Time frame: up to day 11

  6. AUC of SHR4640 dosed after high-fat meal in 7.5mg dose group

    Time frame: up to day 11

  7. T1/2 of SHR4640 dosed after high-fat meal in 7.5mg dose group

    Time frame: up to day 11

  8. Tmax of SHR4640 dosed after high-fat meal in 7.5mg dose group

    Time frame: up to day 11

  9. Changes in serum uric acid concentration from baseline

    absolute and percent changes in serum acid concentration

    Time frame: up to day 4; up to day 11 for 7.5mg dose group

  10. Changes in urinary uric acid excretion from baseline

    percent changes in urinary uric acid excretion from baseline

    Time frame: up to day 4; up to day 11 for 7.5mg dose group

07

Study locations

1 site
  • Southwest Hospital
    Chongqing, Sichuan 400038, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2015 to primary completion in Feb 2017, 15 months.

Of 37 industry-sponsored phase 1 interventional studies under Gout, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 14. This study's 15 months is above that.

Counting every sponsor, half of 41 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2016
First posted
Jun 28, 2016
StartActual
Nov 2015
Primary completionActual
Feb 2017
CompletionActual
Feb 2017
Last update
Feb 28, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02815839
Responsible party
Sponsor
First posted
Jun 28, 2016
Start date
Nov 2015
Primary completion
Feb 2017
Completion
Feb 2017
Last update
Feb 28, 2017
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruzinurad

Start the discussion